Latest news with #JCSanchez
Associated Press
7 days ago
- Business
- Associated Press
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation (CNC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.) – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene and certain of Centene's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Centene class action lawsuit must be filed with the court no later than Monday, September 8, 2025. CASE ALLEGATIONS: Centene is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals. The Centene class action lawsuit alleges that defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Centene's projected revenue outlook and anticipated growth while also touting enrollment rates and low morbidity. In truth, Centene's optimistic reports and promises regarding Centene's inflated guidance fell short of reality when a preliminary analysis of over two-thirds of Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity, according to the complaint. The Centene class action lawsuit further alleges that, on July 1, 2025, Centene withdrew its 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of Centene's marketplace membership, was lower than expected, according to the complaint. Centene also stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75, the Centene class action lawsuit alleges. On this news, the price of Centene stock fell by more than 40%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Centene securities during the class period to seek appointment as lead plaintiff in the Centene class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Centene class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Centene class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Centene class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Globe and Mail
21-07-2025
- Business
- Globe and Mail
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation (CNC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that the Centene class action lawsuit – captioned Lunstrum v. Centene Corporation, No. 25-cv-05659, and pending in the Southern District of New York – seeks to represent purchasers or acquirers of Centene Corporation (NYSE: CNC) securities and charges Centene as well as certain of Centene's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Centene class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ Lead plaintiff motions for the Centene class action lawsuit must be filed with the court no later than September 8, 2025. CASE ALLEGATIONS: Centene is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals. The Centene class action lawsuit alleges that defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Centene's projected revenue outlook and anticipated growth while also touting enrollment rates and low morbidity. In truth, Centene's optimistic reports and promises regarding Centene's inflated guidance fell short of reality when a preliminary analysis of over two-thirds of Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity, according to the complaint. The Centene class action lawsuit further alleges that, on July 1, 2025, Centene withdrew its 2025 guidance. Particularly, following an analysis of the 2025 Health Insurance Marketplace, Centene's overall market growth across 22 states, or 72% of Centene's marketplace membership, was lower than expected, according to the complaint. Centene also stated that this preliminary analysis resulted in a reduction of its previously issued guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75, the Centene class action lawsuit alleges. On this news, the price of Centene stock fell by more than 40%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Centene securities during the class period to seek appointment as lead plaintiff in the Centene class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Centene class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Centene class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Centene class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Associated Press
21-07-2025
- Business
- Associated Press
INVESTOR DEADLINE TOMORROW: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, inclusive (the 'Class Period'). Captioned Lerner v. Organon & Co., No. 25-cv-12983 (D.N.J.), the Organon class action lawsuit charges Organon as well as certain of Organon's top executives with violations of the Securities Exchange Act of 1934. A previously filed complaint is captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.). If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Organon class action lawsuit must be filed with the court no later than this upcoming Tuesday, July 22, 2025. CASE ALLEGATIONS: Organon develops and delivers health solutions through prescription therapies and medical devices. The Organon class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Organon faced a higher risk of loss of exclusivity and price erosion as to Nexplanon than implied by its Class Period statements; (ii) as a result, Organon's long-term Nexplanon sales growth was not as strong as defendants' portended during the Class Period, and would not reach $1 billion by the end of fiscal year 2025 (much less upwards of $1.5 billion after that), and that Organon was likely not on track to achieve the $1 billion milestone payment from Merck & Co. on its Nexplanon sales thereafter; (iii) thus, Organon was not on track to achieve, much less maintain, the $1 billion in free cash flow required to sustain its outsized dividend; (iv) consequently, Organon was also not on track to maintain 4.0x debt leverage; (v) as such, Organon might not be able to maintain its corporate debt ratings at their then-current Class Period levels; and (vi) as a result, Organon lacked a reasonable basis to report its Class Period business metrics and financial projections. The Organon class action lawsuit further alleges that on May 1, 2025, in connection with announcing its first quarter 2025 financial results for the interim period ended March 31, 2025, Organon slashed its dividend by 90%, down from 28¢ per share per quarter ($1.16 per share annually) down to just 2¢ per share per quarter (or 8¢ per share annually). According to a quote attributed to Organon's CEO, defendant Kevin Ali, in the press release Organon issued that day, it had 'reset [its] capital allocation priorities to accelerate progress towards deleveraging, enabling a path to achieve a net leverage ratio of below 4.0x by year-end,' emphasizing that Organon's 'primary capital allocation priority' was now 'maintaining lower leverage.' On this news, the price of Organon stock fell more than 27%. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Organon publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Organon class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Organon class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Organon class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Organon class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Associated Press
16-07-2025
- Business
- Associated Press
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025, inclusive (the 'Class Period'), have until Tuesday, July 22, 2025 to seek appointment as lead plaintiff of the Red Cat class action lawsuit. Captioned Olsen v. Red Cat Holdings, Inc., No. 25-cv-05427 (D.N.J.), the Red Cat class action lawsuit charges Red Cat and certain of Red Cat's current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Red Cat class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Red Cat, together with its subsidiaries, provides products and solutions to drone industry. Red Cat's products include, among others, the 'Teal 2' drone, a small, unmanned aircraft system designed to purportedly 'Dominate the Night' during nighttime military operations. The Red Cat class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Red Cat's Salt Lake City facility's production capacity, and defendants' progress in developing the same, was overstated; and (ii) the overall value of Red Cat's Short Range Reconnaissance Program of Record Tranche 2 contract (the 'SRR Contract') was overstated. The Red Cat class action lawsuit further alleges that on July 27, 2023, Red Cat revealed that its Salt Lake City facility could only currently produce 100 drones per month, the facility was still being built, refined, and expanded, and that construction of the facility was only 'substantially completed' and potentially could reach a production capacity of 1,000 drones per month over the next 2 to 3 years, but only with additional capital investments and manufacturing efficiencies realized. On this news, the price of Red Cat stock fell nearly 9%, according to the complaint. Then, on September 23, 2024, the Red Cat class action lawsuit further alleges that Red Cat announced its financial results for the first quarter of fiscal year 2025, reporting losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing consensus estimates by $1.07 million. According to the complaint, Red Cat further disclosed that Red Cat had spent 'the past four months . . . retooling [the Salt Lake City facility] and preparing for high volume production,' while admitting that a 'pause in manufacturing of Teal 2 and building Army prototypes impacted Teal 2 sales' because, among other things, Red Cat 'couldn't produce and sell Teal 2 units while retooling [its] factory.' The Red Cat class action lawsuit alleges that on this news, the price of Red Cat stock fell more than 25%. Finally, the Red Cat class action lawsuit further alleges that on January 16, 2025, Kerrisdale Capital published a report alleging that '[t]he SRR contract that Red Cat won in November and preemptively announced without the Army's permission is much smaller and less favorable than management as intimated,' and that '[i]t's highly implausible that a mass-production facility for manufacturing drones has been built at any point in the last two years for less than $1 million.' On this news, the price of Red Cat stock fell more than 21% over two trading sessions, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Red Cat securities during the Class Period to seek appointment as lead plaintiff in the Red Cat class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Red Cat class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Red Cat class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Red Cat class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Globe and Mail
09-07-2025
- Business
- Globe and Mail
INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Easterly ROCMuni High Income Municipal Bond Fund, Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm – RMJAX, RMHIX, and RMHVX
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Easterly ROCMuni High Income Municipal Bond Fund (RMJAX, RMHIX, and RMHVX) – formerly Principal Street High Income Municipal Fund (GSTAX, GSTEX, and GSTFX) – focused on whether the fund and/or its managers made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Easterly ROCMuni High Income investigation or if you are an Easterly ROCMuni High Income investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@ THE FUND: Easterly ROCMuni High Income Municipal Bond Fund is a high-yield municipal bond mutual fund. THE REVELATION: On June 17, 2025, Bloomberg published an article titled 'Easterly High-Yield Muni Fund Plunges Nearly 50% in Sales Dump,' reporting that '[t]he Easterly RocMuni High Income Municipal Bond Fund net-asset value fell to $3.16 on Monday from $6.15 on Friday morning' and that '[i]ts assets have declined to about $67 million from about $245 million at the end of February.' ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
